Stockreport

Innate Pharma Reports Full Year 2024 Financial Results and Business Update

Innate Pharma S.A. - American Depositary Shares  (IPHA) 
PDF FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndromeNew data, including lacutamab improved health-related quality of life [Read more]